Business Context and Reporting Period
Company: Alterity Therapeutics Limited (a development stage enterprise)
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Date: November 21, 2025
Principal Executive Office: Level 14, 350 Collins Street, Melbourne, Victoria 3000, Australia
Reporting Status: Files annual reports under Form 20-F.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on corporate governance changes rather than financial performance.
Material Changes
- Board Changes: The filing includes Exhibit 99.1 titled "Alterity Board Changes," indicating updates to the company's board of directors.
Guidance, Outlook, and Risks
The filing text does not provide specific guidance, outlook, management commentary, risks, contingencies, or unusual items. The document serves primarily to incorporate board change information into existing Registration Statements on Form S-8 and Form F-3.
Investor Verification Checklist
- Review Exhibit 99.1 ("Alterity Board Changes") for details on specific director appointments or resignations.
- Verify the impact of board changes on the company's strategic direction as a development stage enterprise.
- Check subsequent filings for the next available financial data, as this 6-K contains no financial statements.